Mahogany: A phase 3 trial of zanubrutinib and anti-CD20 in people with relapsed or refractory follicular or marginal zone lymphoma

This trial is testing the medication zanubrutinib plus anti-CD20 against current treatment options in adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL) which has returned after (relapsed) or not responded (is refractory) to treatment. 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05100862

Trial aim and background  

The aim of this trial is to compare zanubrutinib along with monoclonal CD20 antibodies in relapsed and refractory FL and MZL. There are two aspects to the trial depending on the type of lymphoma:

  • Patients with relapsed or refractory FL will receive zanubrutinib plus obinutuzumab or the standard treatment lenalidomide plus rituximab (R2)
  • Patients with relapsed or refractory MZL will receive zanubrutinib plus lenalidomide or R2

The effectiveness of these treatments will be measured with progression-free survival.

Who can enter

People with FL or MZL which has relapsed after, or become refractory to at least one systemic therapy including a monoclonal CD20 antibody may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • Huddersfield Royal Infirmary, Huddersfield
  • University College Hospital, London
  • Derriford Hospital, Plymouth
  • Beatson West of Scotland Cancer Centre, Glasgow
  • The Christie Hospital, Manchester
  • The Leeds Teaching Hospitals NHS Trust, Leeds
  • Southampton General Hospital, Southampton

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.clinicaltrials.gov/study/NCT05100862

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances